Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Replimune Group Inc (REPL)
NASDAQ:REPL
Holding REPL?
Track your performance easily
REPL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.92 - $18.12
Previous Close$10.46
Volume700.25K
Average Volume (3M)833.88K
Market Cap
$714.64M
Enterprise Value$321.47M
Total Cash (Recent Filing)$469.12M
Total Debt (Recent Filing)$75.95M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Oct 31, 2024EPS Estimate
-$0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.34
Shares Outstanding68,321,396
10 Day Avg. Volume664,437
30 Day Avg. Volume833,882
Standard Deviation0.24
R-Squared0.07
Alpha0.00800
Financial Highlights & Ratios
Price to Book (P/B)2.01
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.12
Forecast
1Y Price Target
$15.00Price Target Upside35.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Replimune Group News
Bulls Say, Bears Say
Bulls Say
Clinical DataREPL presented positive RP1 data from the primary analysis of the IGNYTE cohort by independent central review.
FinancialsReplimune ended F4Q24 with ~$420.7M in cash, cash equivalents, and marketable securities, extending the operational runway into calendar 2H26.
Regulatory PathResults support potential accelerated approval of RP1 + Opdivo in anti-PD1 failed melanoma patients, with an expected BLA submission.
Bears Say
EarningsReplimune recorded a net loss of $0.83 per share, modestly wider than the estimated net loss of $0.74 per share.
Financial PerformanceThe CERPASS failure last year is a setback.
Financial PerformanceThe failure of RP1 in the CERPASS study on primary response-based endpoints in CSCC is considered a setback.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
REPL FAQ
What was Replimune Group Inc’s price range in the past 12 months?
Replimune Group Inc lowest stock price was $4.92 and its highest was $18.12 in the past 12 months.
What is Replimune Group Inc’s market cap?
Currently, no data Available
When is Replimune Group Inc’s upcoming earnings report date?
Replimune Group Inc’s upcoming earnings report date is Oct 31, 2024 which is in 42 days.
How were Replimune Group Inc’s earnings last quarter?
Replimune Group Inc released its earnings results on Aug 08, 2024. The company reported -$0.78 earnings per share for the quarter, beating the consensus estimate of -$0.857 by $0.077.
Is Replimune Group Inc overvalued?
According to Wall Street analysts Replimune Group Inc’s price is currently Undervalued.
Does Replimune Group Inc pay dividends?
Replimune Group Inc does not currently pay dividends.
What is Replimune Group Inc’s EPS estimate?
Replimune Group Inc’s EPS estimate is -$0.83.
How many shares outstanding does Replimune Group Inc have?
Replimune Group Inc has 68,321,396 shares outstanding.
What happened to Replimune Group Inc’s price movement after its last earnings report?
Replimune Group Inc reported an EPS of -$0.78 in its last earnings report, beating expectations of -$0.857. Following the earnings report the stock price went up 2.717%.
Which hedge fund is a major shareholder of Replimune Group Inc?
Among the largest hedge funds holding Replimune Group Inc’s share is Baker Bros Advisors LP. It holds Replimune Group Inc’s shares valued at 90M.
---
Replimune Group Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (35.99% Upside)
$15.00 (35.99% Upside)
Blogger Sentiment
Bullish
REPL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 891.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $91.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-41.53%
12-Months-Change
Fundamentals
Return on Equity
-46.79%
Trailing 12-Months
Asset Growth
-11.41%
Trailing 12-Months
Company Description
Replimune Group Inc
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
---
REPL Stock 12 Month Forecast
Average Price Target
$15.00
▲(35.99% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Alaunos Therapeutics
―
Oncternal Therapeutics
―
Adicet Bio
―
Best Analysts Covering REPL
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+7.14%
assigned a buy rating 4 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +7.14% per trade.
---